Please login to the form below

Not currently logged in
Email:
Password:

filibuvir

This page shows the latest filibuvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie gets 'breakthrough' status for hepatitis C regimen

AbbVie gets 'breakthrough' status for hepatitis C regimen

In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

Latest news

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    pipeline. The decision to drop filibuvir, reported by the Wall Street Journal on Friday, effectively means that Pfizer has withdrawn from the race to develop a non-interferon-based regimen for ... Filibuvir (also known as PF-00868554) is a non-nucleoside

  • HCV hope on the horizon

    Tibotec). . Among the polymerase inhibitors, the most advanced in development is Pfizer's non-nucleoside compound filibuvir at phase II.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics